Compare · NVO vs RADX
NVO vs RADX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Radiopharm Theranostics Limited (RADX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RADX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 3411.0x RADX ($53.7M).
- Over the past year, NVO is down 45.7% and RADX is down 16.6% - RADX leads by 29.1 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for RADX).
- NVO has more recent analyst coverage (25 ratings vs 2 for RADX).
- Company
- Novo Nordisk A/S
- Radiopharm Theranostics Limited
- Price
- $41.01-4.51%
- $4.27-5.01%
- Market cap
- $183.15B
- $53.7M
- 1M return
- -10.44%
- +0.71%
- 1Y return
- -45.66%
- -16.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest RADX
- H.C. Wainwright initiated coverage on Radiopharm Theranostics with a new price target
- SEC Form 6-K filed by Radiopharm Theranostics Limited
- A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
- SEC Form 3 filed by new insider Voliotis Dimitris
- New insider Hopper Paul claimed ownership of 147,721,428 units of Ordinary Shares (SEC Form 3)
- New insider Laurita Aaron James claimed ownership of 26,357 units of Ordinary Shares (SEC Form 3)
- Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026
- SEC Form 6-K filed by Radiopharm Theranostics Limited
- Radiopharm Theranostics Reports Business Update